Kite Pharma announces pricing of IPO
23/06/2014 15:40
Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products for the treatment of cancer, today announced the pricing of its initial public offering of 7,500,000 shares of its common stock at a price to the public of USD 17 per share. The shares are expected to begin trading on The NASDAQ Global Select Market on June 20, 2014 under the symbol "KITE". In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,125,000 shares of common stock. Jefferies LLC, Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Stifel is acting as co-manager.
23/06/2014 15:40
Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products for the treatment of cancer, today announced the pricing of its initial public offering of 7,500,000 shares of its common stock at a price to the public of USD 17 per share. The shares are expected to begin trading on The NASDAQ Global Select Market on June 20, 2014 under the symbol "KITE". In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,125,000 shares of common stock. Jefferies LLC, Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Stifel is acting as co-manager.
